First Manhattan’s Acer Therapeutics Inc ACER Stock Holding History

First Manhattan’s Portfolio ACER Stock Details ACER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,000	Closed	-$11K	–	1425
2019 Q2	$11K	Sell	3,000 -10,000	-77%	-$191K	﹤0.01%	1174
2019 Q1	$315K	Hold	13,000	–	–	﹤0.01%	629
2018 Q4	$261K	Buy	13,000 +4,000	+44%	+$92.1K	﹤0.01%	643
2018 Q3	$277K	Buy	9,000 +4,000	+80%	+$107K	﹤0.01%	672
2018 Q2	$108K	Hold	5,000	–	–	﹤0.01%	806
2018 Q1	$96K	Hold	5,000	–	–	﹤0.01%	813
2017 Q4	$69K	Buy	+5,000	New	+$81.4K	﹤0.01%	939

Other funds holding ACER

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan's ACER Position: Q3 2019 in Review

First Manhattan sold out of Acer Therapeutics Inc (ACER) in Q3 2019, closing a stake of 3,000 shares — an estimated $11K sold.

First Manhattan first reported a position in ACER in Q4 2017 and held it in 7 quarters. The position peaked at $315K in Q1 2019. 40 funds tracked by Wall St. Rank hold ACER as of Q3 2019.

First Manhattan reported no remaining Acer Therapeutics Inc position as of Q3 2019 after selling out during the quarter.
First Manhattan sold 3,000 Acer Therapeutics Inc shares in Q3 2019, an estimated $11K.
First Manhattan first reported a position in Acer Therapeutics Inc in Q4 2017 and held it in 7 quarters.
First Manhattan's Acer Therapeutics Inc position peaked at $315K in Q1 2019.
40 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q3 2019.

Based on First Manhattan's 13F filing for Q3 2019, filed 13 Nov 2019.